Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery

QR Code

Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery

Background. Psoriasis is an independent risk factor for cardiovascular diseases (CVD). One of the markers associated with the CVD course is epicardial fatty tissue (EFT) that is thicker in psoriasis patients. EFT assessment can be used as a useful indicator of CVD in psoriasis patients. The data abo...

Full description

Saved in:

Bibliographic Details
Main Authors:	Leyla S. Namazova-Baranova, Eduard T. Ambarchyan, Vladislav V. Ivanchikov, Anastasia D. Kuzminova, Anna G. Shandra, Elena A. Vishneva, Grigorii V. Revunenkov, Kirill A. Valyalov
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2023-11-01
Series:	Вопросы современной педиатрии
Subjects:	psoriasis epicardial fatty tissue children ustekinumab secukinumab adalimumab
Online Access:	https://vsp.spr-journal.ru/jour/article/view/3302
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and Safety of Adalimumab and Secukinumab in Erythrodermic Psoriasis: A Single Centre Retrospective Study
by: Yachen Wang, et al.
Published: (2025-07-01)

TNF-α Inhibitor-Induced Psoriasis and Psoriatic Alopecia in Adolescent with Ulcerative Colitis: Clinical Case
by: Eduard T. Ambarchyan, et al.
Published: (2023-11-01)

Leptin and Epicardial Fat: New Markers of Psoriasis in Children? Prospective Cross-Sectional Study
by: Eduard T. Ambarchyan, et al.
Published: (2022-07-01)

Evaluation of Eating Behavior in Children with Psoriasis: Retrospective Cross Sectional Study
by: Vladislav V. Ivanchikov, et al.
Published: (2024-11-01)

Biological Therapy Survivability in Children with Psoriasis: Cohort Study
by: Roman A. Ivanov, et al.
Published: (2021-11-01)

RESULTS OF USTEKINUMAB TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS IN THE RUSSIAN FEDERATION ACCORDING TO THE DATA OF PSUMMIT 1 AND PSUMMIT 2
by: Yu. L. Korsakova, et al.
Published: (2015-04-01)

Comparative Evaluation of the Treatment Efficacy and Safety of TNFα and IL12/23 Inhibitors in Children With Psoriasis
by: Nikolay N. Murashkin, et al.
Published: (2019-02-01)

Ustekinumab Efficacy and Safety in Children with Plaque, Erythrodermic and Palmoplanar Forms of Psoriasis: Retrospective Cohort Study
by: Nikolay N. Murashkin, et al.
Published: (2020-12-01)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021-05-01)

Complete treatment experience on psoriasis patients with secukinumab in real practice in Krasnodar region
by: L. S. Kruglova, et al.
Published: (2021-06-01)

Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
by: E. A. Pyadushkina, et al.
Published: (2021-02-01)

Disease-Modifying Treatment of Psoriasis in Children
by: Nikolay N. Murashkin, et al.
Published: (2024-11-01)

Difficulties in choosing a biologic disease-modifying anti-rheumatic drug for the treatment of psoriasis and psoriatic arthritis
by: I. M. Marusenko, et al.
Published: (2019-03-01)

THE POSSIBILITIES AND RESULTS OF INDIRECT COMPARISON OF BIOLOGICAL AGENTS IN ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-12-01)

Current views on the pharmacotherapy of psoriatic arthritis
by: G. G. Taradin, et al.
Published: (2016-01-01)

Ustekinumab Efficacy in Children with Palmoplantar Psoriasis: Case Series
by: Maria A. Leonova, et al.
Published: (2024-11-01)

Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
by: Leyla S. Namazova-Baranova, et al.
Published: (2021-11-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

THE FIRST RUSSIAN EXPERIENCE OF ADALIMUMAB TREATMENT IN PSORIATIC ARTHRITIS
by: Elena Yurievna Loginova, et al.
Published: (2010-06-01)

Efficacy and safety of adalimumab biosimilar GP2017 in a 24-month treatment period for plaque psoriasis: real-life experience from Emilia-Romagna centers, Italy
by: Marco May Lee, et al.
Published: (2025-07-01)

RESULTS OF EVALUATING THE EFFICACY OF SECUKINUMAB VERSUS ADALIMUMAB IN TREATING PSORIATIC ARTHRITIS BY USING THE MATCHING-ADJUSTED INDIRECT COMPARISON METHOD
by: T. V. Korotaeva
Published: (2016-12-01)

Efficacy of interleukin-17 inhibitors in psoriasis patients: a comparative non-randomized study
by: Arfenya E. Karamova, et al.
Published: (2025-06-01)

MANAGEMENT OF A PATIENT WITH SEVERE COURSE OF PSORIATIC ARTHRITIS
by: E. I. Alexeeva, et al.
Published: (2013-05-01)

Inflammatory Bowel Diseases in Children: Modern Achievements in Diagnostics and Therapy
by: A. I. Khavkin, et al.
Published: (2024-01-01)

Experience of using secukinumab in the treatmentof patients with psoriasis
by: N. V. Zilberberg, et al.
Published: (2021-11-01)

Successful Treatment with Secukinumab in a Psoriasis Patient on Hemodialysis
by: Xiao Y, et al.
Published: (2025-07-01)

Secukinumab-induced Crohn’s disease in a psoriasis patient: a case report highlighting paradoxical reactions to IL-17 inhibition
by: Huiling Dai, et al.
Published: (2025-07-01)

Potential Effects of Some Factors on Psoriasis Course in Children
by: Svetlana G. Gubanova, et al.
Published: (2024-07-01)

Diagnóstico de la tuberculosis latente en la era de la terapia biológica
by: María Carolina Ruiz, et al.
Published: (2019-02-01)

New Possibilities for the Treatment of Crohn’s Disease
by: Z. A. Mamieva, et al.
Published: (2019-12-01)

COVID-19 Dermatological Manifestations in Children
by: Vladislav V. Ivanchikov, et al.
Published: (2022-05-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Evaluation of the health care budget impact of secukinumab treatment in patients with ankylosing spondylitis
by: S. K. Zyryanov, et al.
Published: (2017-04-01)

Results of direct comparison of the clinical efficacy of ixekizumab and adalimumab: data from the SPIRIT H2H study
by: T. V. Korotaeva
Published: (2020-09-01)

Hepatotoxicity Induced by Adalimumab in Chronic Plaque Psoriasis Patient: A Case Report
by: Algarzae NK, et al.
Published: (2025-07-01)

CLINICAL EXPERIENCE WITH USTEKINUMAB IN THE TREATMENT OF EARLY PSORIATIC ARTHRITIS USING TREAT-TO-TARGET STRATEGY
by: E. Yu. Loginova, et al.
Published: (2015-09-01)

INTERLEUKIN-17A IS A NEW TARGET OF ANTICYTOKINE THERAPY FOR ANKYLOSING SPONDYLITIS
by: Sh. F. Erdes
Published: (2016-09-01)

Experience in using secukinumab in patients with axial psoriatic arthritis
by: E. E. Gubar, et al.
Published: (2020-11-01)

Administration Details of Genetically Engineered Biologic Drug (Ustekinumab) in Children with Psoriasis and Comorbid Metabolic Syndrome or in Case of Previous Biological Therapy Failure: Case Studies
by: Roman A. Ivanov, et al.
Published: (2022-11-01)

A case of vitiligo regression in a patient with psoriasis and psoriatic arthritis receiving adalimumab therapy
by: N. S. Rudneva, et al.
Published: (2021-12-01)